Department of Parasitology and Tropical Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Division of Bio Bigdata, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Chungbuk 28159, Republic of Korea.
Phytomedicine. 2022 Jul 20;102:154167. doi: 10.1016/j.phymed.2022.154167. Epub 2022 May 13.
New antimalarial agents are needed to combat emerging resistance to the currently available drugs. In the pathology of cerebral malaria, platelets play a central role by binding infected and uninfected red cells and the endothelium. Since Petasites japonicus extract was reported as an effective inhibitor of platelet activation, we examined the antimalarial activities of the P. japonicus extract.
This study aimed to evaluate the impact of P. japonicus extract prepared from whole plants on malarial infection.
The P. japonicus extract were characterized by high-performance liquid chromatography (HPLC) profiling. Antimalarial activity of the P. japonicus ethanolic extract was evaluated in vitro using chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) P. berghei strains. Also, the in vivo activity of the extract was evaluated in P. berghei-infected mice via oral administration followed by a four-day suppressive test to measure the hematological parameters. In addition, platelet activation signaling induced by the P. japonicus extract in P. berghei infection was evaluated.
In HPLC study, catechin, rutin, liquiritin, 3,4-di-O-caffeoylquinic acid, 3,5-di-O-caffeoylquinic acid, and 4,5-di-O-caffeoylquinic acid were identified in P. japonicus extract. Exposure to the P. japonicus extract significantly inhibited both CQ-sensitive (3D7) and resistant (Dd2) strains of P. falciparum with IC values of 8.48 ± 1.70 and 7.83 ± 6.44 μg/ml, respectively. Administration of the P. japonicus extract also resulted in potent antimalarial activities in P. berghei-infected mice with no associated toxicity. The treatment also improved the hematologic parameters. In addition, the survived mice from P. berghei infection exhibited the inhibition of collagen-induced platelet aggregation by attenuated glycoprotein VI (GPVI) downstream signaling.
P. japonicus extracts promote antimalarial effects both in vitro and in vivo. In addition, the effects appear to be induced by the inhibition of collagen-induced platelet activation related to attenuated GPVI downstream signaling. Further studies to identify and characterize the antimalarial compounds in P. japonicus will promote the development of new drugs.
需要新的抗疟药物来对抗目前可用药物出现的耐药性。在脑型疟疾的病理中,血小板通过与感染和未感染的红细胞以及内皮细胞结合而发挥核心作用。由于朝鲜蓟提取物被报道为血小板激活的有效抑制剂,因此我们研究了朝鲜蓟提取物的抗疟活性。
本研究旨在评估来自全株植物的朝鲜蓟提取物对疟原虫感染的影响。
采用高效液相色谱法(HPLC)对朝鲜蓟提取物进行了表征。用氯喹敏感型(3D7)和氯喹耐药型(Dd2)伯氏疟原虫株在体外评价朝鲜蓟乙醇提取物的抗疟活性。此外,通过口服给药并进行为期四天的抑制试验来评估提取物在感染伯氏疟原虫的小鼠中的体内活性,以测量血液学参数。此外,还评价了朝鲜蓟提取物在伯氏疟原虫感染中诱导的血小板激活信号。
在 HPLC 研究中,鉴定出朝鲜蓟提取物中的儿茶素、芦丁、甘草素、3,4-二-O-咖啡酰奎宁酸、3,5-二-O-咖啡酰奎宁酸和 4,5-二-O-咖啡酰奎宁酸。暴露于朝鲜蓟提取物显著抑制了氯喹敏感型(3D7)和耐药型(Dd2)疟原虫株,IC 值分别为 8.48 ± 1.70 和 7.83 ± 6.44μg/ml。朝鲜蓟提取物给药还导致感染伯氏疟原虫的小鼠产生有效的抗疟活性,而无相关毒性。该治疗还改善了血液学参数。此外,从伯氏疟原虫感染中存活的小鼠表现出通过减弱糖蛋白 VI(GPVI)下游信号来抑制胶原诱导的血小板聚集。
朝鲜蓟提取物在体外和体内均具有促进抗疟作用。此外,这些作用似乎是通过抑制与减弱的 GPVI 下游信号相关的胶原诱导的血小板激活而产生的。进一步研究以鉴定和表征朝鲜蓟中的抗疟化合物将促进新药的开发。